SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Ototoxicity

Interventions

DRUG: Placebo
DRUG: SPI-1005 Ebselen 200mg Capsule x1
DRUG: SPI-1005 Ebselen 200mg Capsule x2
DRUG: SPI-1005 Ebselen 200mg Capsule x3

Sponsor

Sound Pharmaceuticals, Incorporated

Collaborators

[object Object]
[object Object]